

Richard I Fisher

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11124566/richard-i-fisher-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

178 papers	38,518 citations	69 h-index	180 g-index
180 ext. papers	42,679 ext. citations	7.7 avg, IF	6.26 L-index

#	Paper	IF	Citations
178	A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 24-25	2.2	2
177	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3003-3011	2.2	33
176	Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1934-1941	1.9	3
175	Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells and. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1179	6.1	
174	Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 356-364.e3	2	53
173	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1790-1799	2.2	156
172	Retraction: Obatoclox Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells and. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1180	6.1	1
171	Real-World Application of National Comprehensive Cancer Network (NCCN) Testing Guidelines in Diffuse Large B-Cell Lymphoma (DLBCL) Results in Underdiagnosis of Double-Hit Lymphoma. <i>Blood</i> , 2019 , 134, 3426-3426	2.2	0
170	Intracloal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016. <i>Blood</i> , 2019 , 134, 2771-2771	2.2	
169	Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 135-141	2	27
168	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. <i>Lancet Haematology,the</i> , 2018 , 5, e102-e108	14.6	15
167	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 700-707	4.7	9
166	A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. <i>American Journal of Hematology</i> , 2018 , 93, 486-493	7.1	25
165	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , 2018 , 36, 697-703	2.2	50
164	RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017 , 176, 759-769	4.5	26
163	Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). <i>Leukemia and Lymphoma</i> , 2017 , 58, 1814-1822	1.9	9
162	Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. <i>Journal of Cancer Survivorship</i> , 2017 , 11, 32-40	5.1	1

161	Diffuse Large B-Cell Lymphoma Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 196-231	7.3	60
160	Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2016 , 57, 635-43	1.9	19
159	Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016. <i>Blood</i> , 2016 , 128, 616-616	2.2	2
158	Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. <i>British Journal of Haematology</i> , 2016 , 172, 208-18	4.5	34
157	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1067-79	7.3	80
156	A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2359-69	1.9	23
155	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2020-7	2.2	184
154	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2399-404	2.2	82
153	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1936-42	2.2	24
152	Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1482-90	2.2	50
151	Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. <i>Blood</i> , 2015 , 125, 236-41	2.2	15
150	Is observation dead in follicular lymphoma? No, but the apoptosis pathway has been activated. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 363-6	7.3	2
149	Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015 , 171, 530-8	4.5	39
148	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1221-3	2.2	3
147	Reply to G. Karamida et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4121-2	2.2	1
146	R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. <i>British Journal of Haematology</i> , 2014 , 166, 382-9	4.5	24
145	Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014 , 89, 639-45	7.1	20
144	Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3059-68	2.2	2407

143	Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3048-58	2.2	927
142	Non-Hodgkin's lymphomas, version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1282-303	7.3	103
141	Non-Hodgkin's lymphomas, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 916-46	7.3	31
140	Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2. <i>PLoS ONE</i> , 2014 , 9, e95184	3.7	29
139	The role of myeloablation for lymphoma. <i>New England Journal of Medicine</i> , 2014 , 370, 575-6	59.2	6
138	Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. <i>Cancer</i> , 2013 , 119, 371-9	6.4	67
137	Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , 2013 , 369, 1681-90	59.2	228
136	Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013 , 31, 314-20	2.2	138
135	Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 692-700	2.2	145
134	Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013 , 31, 684-91	2.2	204
133	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013 , 161, 76-86	4.5	86
132	Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2185-9	1.9	4
131	The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. <i>British Journal of Haematology</i> , 2013 , 161, 43-56	4.5	70
130	A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. <i>Clinical Cancer Research</i> , 2013 , 19, 6624-32	13.9	31
129	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013 , 121, 3547-53	2.2	102
128	Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas. <i>Blood</i> , 2013 , 122, 4375-4375	2.2	5
127	A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. <i>Blood</i> , 2012 , 120, 1210-7	2.2	51
126	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. <i>Blood</i> , 2012 , 120, 3280-7	2.2	159

125	Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 640-47	4.7	8
124	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012 , 490, 116-20	50.4	600
123	Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. <i>Clinical Cancer Research</i> , 2012 , 18, 2210-9	12.9	44
122	A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. <i>Leukemia and Lymphoma</i> , 2012 , 53, 259-62	1.9	58
121	Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1122-32	6.1	29
120	Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. <i>Haematologica</i> , 2012 , 97, 937-42	6.6	51
119	MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study. <i>Blood</i> , 2012 , 120, 543-543	2.2	1
118	Clinical Evaluation and Management of Lymphoma 2011 , 268-286		
117	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 20-47.e30	4.7	83
116	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011 , 470, 115-9	50.4	1068
115	Advanced insights into the biology of malignant lymphomas. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1799-800	2.0	7
114	Novel therapeutics for aggressive non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1876-84	2.4	39
113	Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 1686-97	6.1	53
112	The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. <i>Blood</i> , 2011 , 117, 2807-12	2.2	156
111	Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). <i>British Journal of Haematology</i> , 2010 , 151, 143-51	4.5	72
110	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010 , 463, 88-92	50.4	1149
109	Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. <i>Clinical Cancer Research</i> , 2010 , 16, 2435-42	12.9	23
108	Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1269-77	1.9	27

107	The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. <i>Blood</i> , 2010 , 115, 4478-87	2.2	99
106	Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. <i>Leukemia Research</i> , 2010 , 34, 379-86	2.7	23
105	Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 79-85	4	28
104	A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Blood</i> , 2010 , 116, 415-415	2.2	10
103	Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2009 , 27, 114-9	2.2	184
102	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2009 , 27, e27-e28	2.2	1
101	Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. <i>Cancer Biology and Therapy</i> , 2009 , 8, 808-19	4.6	30
100	A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. <i>British Journal of Haematology</i> , 2009 , 145, 741-8	4.5	69
99	Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2009 , 146, 282-91	4.5	69
98	A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. <i>Leukemia and Lymphoma</i> , 2009 , 50, 728-35	1.9	71
97	Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. <i>Blood</i> , 2009 , 113, 3809-12	2.2	131
96	The Novel Proteasome Inhibitor Carfilzomib Interacts Synergistically with HDAC Inhibitors in ABC- and GC-DLBCL Cells Both in Vitro and In Vivo through Mechanisms Involving JNK Activation, NF- κ B Inactivation, and DNA Damage... <i>Blood</i> , 2009 , 114, 1688-1688	2.2	
95	Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. <i>Science</i> , 2008 , 319, 1676-9	33.3	660
94	Diffuse large B-cell lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2008 , 22, 941-52, ix	3.1	94
93	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 13520-5	11.5	746
92	Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2258-63	2.2	199
91	Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313). <i>Blood</i> , 2008 , 112, 3598-3598	2.2	5
90	Revised response criteria for malignant lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 579-86	2.2	3483

89	B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. <i>Clinical Immunology</i> , 2007 , 122, 139-45	9	137
88	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2007 , 204, 633-43	16.6	160
87	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007 , 109, 4599-606	2.2	183
86	Vorinostat (Suberoylanilide Hydroxamic Acid) in Relapsed or Refractory Hodgkin Lymphoma: SWOG 0517.. <i>Blood</i> , 2007 , 110, 2574-2574	2.2	10
85	Gene Expression Signatures Predict Overall Survival in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.. <i>Blood</i> , 2007 , 110, 348-348	2.2	6
84	Central Nervous System (CNS) Relapse in Aggressive Non-Hodgkin's Lymphoma; Does CNS Prophylaxis Work?.. <i>Blood</i> , 2007 , 110, 520-520	2.2	1
83	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2007 , 110, 692-692	2.2	2
82	Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH.. <i>Blood</i> , 2007 , 110, 2631-2631	2.2	
81	Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4143-9	2.2	228
80	Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3121-7	2.2	1036
79	Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4867-74	2.2	600
78	Molecular diagnosis of Burkitt's lymphoma. <i>New England Journal of Medicine</i> , 2006 , 354, 2431-42	59.2	700
77	Treatment of diffuse large B-cell lymphomas. <i>Seminars in Hematology</i> , 2006 , 43, 205-6	4	3
76	Diffuse large B-cell NHL. <i>Cancer Treatment and Research</i> , 2006 , 131, 121-40	3.5	5
75	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. <i>Blood</i> , 2006 , 107, 4207-13	2.2	227
74	The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications. <i>Current Opinion in Oncology</i> , 2006 , 18, 417-24	4.2	20
73	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. <i>Blood</i> , 2006 , 107, 1101-7	2.2	60
72	Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2006 , 108, 809-809	2.2	9

71	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005 , 106, 3183-90	2.2	304
70	Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7565-73	2.2	204
69	New treatment options have changed the survival of patients with follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8447-52	2.2	341
68	Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. <i>Journal of Clinical Oncology</i> , 2005 , 23, 657-8	2.2	21
67	The PKC δ Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells.. <i>Blood</i> , 2005 , 106, 1483-1483	2.2	9
66	An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar \square) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911.. <i>Blood</i> , 2005 , 106, 352-352	2.2	5
65	Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 18-26	3.5	22
64	Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4302-11	2.2	253
63	Diffuse aggressive lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2004 , 2004, 221-36	3.1	62
62	The epidemiology of non-Hodgkin's lymphoma. <i>Oncogene</i> , 2004 , 23, 6524-34	9.2	301
61	Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. <i>New England Journal of Medicine</i> , 2004 , 351, 2159-69	59.2	1141
60	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. <i>Blood</i> , 2004 , 103, 1251-9	2.2	256
59	Follicular lymphoma international prognostic index. <i>Blood</i> , 2004 , 104, 1258-65	2.2	1348
58	Effect of Adding Rituximab to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).. <i>Blood</i> , 2004 , 104, 158-158	2.2	19
57	Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736.. <i>Blood</i> , 2004 , 104, 3263-3263	2.2	6
56	Venous Thromboembolic Events in Patients with Diffuse Large B cell Non- Hodgkin's Lymphoma.. <i>Blood</i> , 2004 , 104, 4542-4542	2.2	2
55	High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.. <i>Blood</i> , 2004 , 104, 697-697	2.2	
54	Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3512-9	2.2	77

53	Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1996-2003	2.2	47
52	A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. <i>Blood</i> , 2003 , 102, 1606-12	2.2	145
51	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003 , 3, 185-97	24.3	751
50	Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. <i>Journal of Experimental Medicine</i> , 2003 , 198, 851-62	16.6	869
49	The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 529-39	4.7	50
48	Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 607-14	2.2	389
47	Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). <i>Journal of Clinical Oncology</i> , 2003 , 21, 2466-73	2.2	66
46	Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. <i>Seminars in Oncology</i> , 2003 , 30, 3-9	5.5	489
45	Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4411-2	2.2	5
44	The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. <i>New England Journal of Medicine</i> , 2002 , 346, 1937-47	59.2	2971
43	Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 4-5	9.7	7
42	Diffuse large-cell lymphomas: a review of therapy. <i>Clinical Lymphoma and Myeloma</i> , 2001 , 2, 155-63		3
41	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 308-31	4.7	47
40	Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2001 , 19, 750-5	2.2	26
39	Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4238-44	2.2	126
38	Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial. <i>Anti-Cancer Drugs</i> , 2000 , 11, 695-700	2.4	15
37	Interferon does not prolong progression-free survival after ProMACE-MOPP. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3322	2.2	
36	Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2010-6	2.2	66

35	Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma. <i>Chest</i> , 1999 , 116, 470S-473S	5.3	61
34	Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1244	2.2	2910
33	Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , 1998 , 339, 21-6	59.2	753
32	A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. <i>New England Journal of Medicine</i> , 1998 , 339, 1506-14	59.2	1298
31	CHOP therapy: has shorter-course therapy had an impact on lymphomas?. <i>Cancer Investigation</i> , 1998 , 16, 26-32	2.1	3
30	BCL-2 Expression Correlates With Lower Proliferative Activity in the Intermediate- and High-Grade Non-Hodgkin's Lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group Cooperative Laboratory Study. <i>Blood</i> , 1998 , 91, 1391-1398	2.2	38
29	A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification. <i>Hematology/Oncology Clinics of North America</i> , 1997 , 11, 819-46	3.1	7
28	Follicular lymphomas: do histologic subtypes predict outcome?. <i>Hematology/Oncology Clinics of North America</i> , 1997 , 11, 893-900	3.1	34
27	Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years. <i>Cancer</i> , 1994 , 74, 2657-61	6.4	20
26	Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study. <i>Hematological Oncology</i> , 1994 , 12, 75-85	1.3	9
25	Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. <i>Journal of Immunotherapy</i> , 1994 , 15, 147-53	5	52
24	Treatment of aggressive non-hodgkin's lymphomas: Lessons from the past 10 years. <i>Cancer</i> , 1994 , 74, 2657-2661	6.4	1
23	Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , 1993 , 328, 1002-6	59.2	1757
22	Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 1991 , 2 Suppl 1, 33-5	10.3	14
21	Leukemic transformation in polycythemia vera: analysis of risk factors. <i>American Journal of Hematology</i> , 1990 , 34, 32-6	7.1	63
20	Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. <i>New England Journal of Medicine</i> , 1990 , 323, 1723-8	59.2	769
19	Multiple recurrences of acute tumor lysis syndrome in an indolent non-Hodgkin's lymphoma. <i>Cancer</i> , 1985 , 56, 2295-7	6.4	35
18	Deficient helper cell function as a cause of diminished pokeweed mitogen blastogenic responses in patients with non-Hodgkin's lymphomas. <i>Cancer</i> , 1984 , 54, 2936-42	6.4	3

17	Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. <i>Annals of Internal Medicine</i> , 1983 , 98, 304-9	8	267
16	Increased sensitivity of T cells to regulation by normal suppressor cells persists in long-term survivors with Hodgkin's disease. <i>American Journal of Medicine</i> , 1982 , 72, 385-90	2.4	28
15	Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. <i>American Journal of Medicine</i> , 1981 , 71, 967-72	2.4	18
14	Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. <i>Surgical Clinics of North America</i> , 1981 , 61, 1267-77	4	70
13	Peritoneoscopy in the management of ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1981 , 140, 611-9	6.4	62
12	Natural history of malignant lymphomas with divergent histologies at staging evaluation. <i>Cancer</i> , 1981 , 47, 2022-5	6.4	41
11	Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. <i>Annals of Internal Medicine</i> , 1980 , 92, 595-9	8	105
10	Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. <i>American Journal of Medicine</i> , 1979 , 66, 435-43	2.4	156
9	Ovarian cancer: a solid tumor with evidence of normal cellular immune function but abnormal B cell function. <i>American Journal of Medicine</i> , 1979 , 66, 621-4	2.4	19
8	Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. <i>Annals of Internal Medicine</i> , 1979 , 90, 761-3	8	170
7	Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 1978 , 5, 203-9	7.1	33
6	Diffuse histiocytic lymphoma involving the gastrointestinal tract. <i>Cancer</i> , 1978 , 41, 1984-9	6.4	92
5	Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. <i>Cancer</i> , 1978 , 42, 2157-61	6.4	52
4	Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. <i>New England Journal of Medicine</i> , 1978 , 299, 1261-6	59.2	293
3	Chemotherapy of ovarian cancer. <i>Surgical Clinics of North America</i> , 1978 , 58, 143-50	4	12
2	Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. <i>American Journal of Medicine</i> , 1977 , 63, 177-82	2.4	175
1	Advances in the staging and treatment of ovarian cancer. <i>Cancer</i> , 1977 , 39, 967-72	6.4	31